¹⁷⁷Lu-Rosopatamab (¹⁷⁷Lu-J591, ¹⁷⁷Lu-TLX591, ¹⁷⁷Lu-J591, ¹⁷⁷Lu-ATL-101) is the Lutetium-177 labeled J591 anti-PSMA antibody originally developed at the Weill Cornell Medical Center, Cornell University, New York.

J591 is an anti-PSMA (prostate-specific membrane antigen) antibody with high specificity for prostate tumor cells. PSMA (or GCPII or NAAG peptidase) is a zinc metalloenzyme that is expressed in the membranes of many cells, mainly the prostate, but also the kidney, the small intestine, and the central and peripheral nervous system. In fact, PSMA is strongly expressed in the human prostate, being a hundredfold greater than the expression in most other tissues. ¹⁷⁷Lu-Rosopatamab is therefore an ideal drug for the targeting of prostate cancer and its metastases.

A large-scale Phase III trial (the PROSTACT study) in prostate cancer patients was initiated in June 2022 and primary completion is expected by June 2024.

Target/Mechanism: PSMA

Carrier/Ligand: Rosopatamab

Radiation Type: beta electrons (β^–)